Phase II Trial of an Adenovirus/PSA Vaccine for Recurrent Prostate Cancer

The University of Iowa and the Iowa City VA Medical Center are conducting a Phase II trial of a vaccine for the treatment of recurrent prostate cancer. Two protocols are active; one protocol treats hormone naïve patients who have experienced a recent, but continued rise in their serum PSA following initial treatment for their prostate cancer, and a second protocol treats men with hormone refractory prostate cancer. The hypothesis is that the vaccine will induce the production of anti-PSA and, therefore, anti-prostate cancer, immune responses that will cause the destruction of the cancer cells anywhere in the body. Interested patients can contact the Clinical Trial Coordinator Ms. Pamela Zehr at 319-353-8914, pamela-zehr@uiowa.edu or Dr. David Lubaroff at 319-335-8423, david-lubaroff@uowa.edu.